Jean Piero Margaria

Dr. Jean Piero Margaria

University of Turin, Turin, Piedmont, Italy

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2018 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
Carlo C. CampaCarlo C. Campa
Carlo C. Campa
JMJean Piero Margaria
Jean Piero Margaria
ADAbhishek Derle
Abhishek Derle
MGMarco Del Giudice
Marco Del Giudice
MSMaria Chiara De Santis
Maria Chiara De Santis
EHEmilio Hirsch
Emilio Hirsch

10 December 2021 in Science
Verified
Journal Article
Closed access
Federico GulluniFederico Gulluni
Federico Gulluni
LPLorenzo Prever
Lorenzo Prever
HLHuayi Li
Huayi Li
PKPetra Krafcikova
Petra Krafcikova
ICIlaria Corrado
Ilaria Corrado
EHEmilio Hirsch
Emilio Hirsch
ESCRTing lenses away from senescence: ESCRT proteins control membrane fusion in various key cellular processes, but the mechanisms involved are still incompletely understood. Gulluni et al . report that ESCRT recruitment at the cytokinetic bridge is mediated by the binding of an ESCRT-II subunit to the signaling lipid phosphatidylinositol 3,4-bisphosphate (see the Perspective by Brill and Wilde). This pathway acts in parallel to a known cascade driven by a protein called ALIX, but its failure is sufficient to lead to premature senescence in the lens of fish, mouse, and human eyes, where ALIX is expressed at lower levels. These results point to an evolutionarily conserved pathway for the cell-specific control of cytokinesis that serves to protect from senescence and the early onset of cataracts. —SMH

15 March 2019 in Biomolecules
Verified
Journal Article
Open access
PDF file
JMJean Piero Margaria
Jean Piero Margaria
EREdoardo Ratto
Edoardo Ratto
LGLuca Gozzelino
Luca Gozzelino
HLhuayi li
huayi li
EHEmilio Hirsch
Emilio Hirsch
Phosphorylation of inositol phospholipids by the family of phosphoinositide 3-kinases (PI3Ks) is crucial in controlling membrane lipid composition and regulating a wide range of intracellular processes, which include signal transduction and vesicular trafficking. In spite of the extensive knowledge on class I PI3Ks, recent advances in the study of the three class II PI3Ks (PIK3C2A, PIK3C2B and PIK3C2G) reveal their distinct and non-overlapping cellular roles and localizations. By finely tuning membrane lipid composition in time and space among different cellular compartments, this class of enzymes controls many cellular processes, such as proliferation, survival and migration. This review focuses on the recent developments regarding the coordination of membrane trafficking and intracellular signaling of class II PI3Ks through the confined phosphorylation of inositol phospholipids.

23 March 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
JMJean Piero Margaria
Jean Piero Margaria
LMLucia Moretta
Lucia Moretta
JAJose C. Alves-Filho
Jose C. Alves-Filho
EHEmilio Hirsch
Emilio Hirsch
Pulmonary fibrosis is a pathological fibrotic process affecting the lungs of five million people worldwide. The incidence rate will increase even more in the next years due to the long-COVID-19 syndrome, but a resolving treatment is not available yet and usually prognosis is poor. The emerging role of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling in fibrotic processes has inspired the testing of drugs targeting the PI3K/Akt pathway that are currently under clinical evaluation. This review highlights the progress in understanding the role of PI3K/Akt in the development of lung fibrosis and its causative pathological context, including sepsis as well as acute lung injury (ALI) and its consequent acute respiratory distress syndrome (ARDS). We further summarize current knowledge about PI3K inhibitors for pulmonary fibrosis treatment, including drugs under development as well as in clinical trials. We finally discuss how the design of inhaled compounds targeting the PI3K pathways might potentiate efficacy and improve tolerability.

17 July 2020 in Microorganisms
Verified
Journal Article
Open access
PDF file
Sara PetrilloSara Petrillo
Sara Petrillo
GCGiovanna Carrá
Giovanna Carrá
PBPaolo Bottino
Paolo Bottino
EZElisa Zanotto
Elisa Zanotto
MSMaria Chiara De Santis
Maria Chiara De Santis
FAFiorella Altruda
Fiorella Altruda
Rapid and sensitive screening of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential to limit the spread of the global pandemic we are facing. Quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) is currently used for the clinical diagnosis of SARS-CoV-2 infection using nasopharyngeal swabs, tracheal aspirates, or bronchoalveolar lavage (BAL) samples. Despite the high sensitivity of the qRT-PCR method, false negative outcomes might occur, especially in patients with a low viral load. Here, we developed a multiplex qRT-PCR methodology for the simultaneous detection of SARS-CoV-2 genome (N gene) and of the human RNAse P gene as internal control. We found that multiplex qRT-PCR was effective in detecting SARS-Cov-2 infection in human specimens with 100% sensitivity. Notably, patients with few copies of SARS-CoV-2 RNA (<5 copies/reaction) were successfully detected by the novel multiplex qRT-PCR method. Finally, we assessed the efficacy of multiplex qRT-PCR on human nasopharyngeal swabs without RNA extraction. Collectively, our results provide evidence of a novel and reliable tool for SARS-CoV-2 RNA detection in human specimens, which allows the testing capacity to be expanded and the RNA extraction step to be bypassed.

27 May 2022 in Gut
Verified
Journal Article
Open access
PDF file
MSMaria Chiara De Santis
Maria Chiara De Santis
LGLuca Gozzelino
Luca Gozzelino
JMJean Piero Margaria
Jean Piero Margaria
ACAndrea Costamagna
Andrea Costamagna
EREdoardo Ratto
Edoardo Ratto
MMMiriam Martini
Miriam Martini
Objective Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with limited therapeutic options. However, metabolic adaptation to the harsh PDAC environment can expose liabilities useful for therapy. Targeting the key metabolic regulator mechanistic target of rapamycin complex 1 (mTORC1) and its downstream pathway shows efficacy only in subsets of patients but gene modifiers maximising response remain to be identified. Design Three independent cohorts of PDAC patients were studied to correlate PI3K-C2γ protein abundance with disease outcome. Mechanisms were then studied in mouse (KPC mice) and cellular models of PDAC, in presence or absence of PI3K-C2γ (WT or KO). PI3K-C2γ-dependent metabolic rewiring and its impact on mTORC1 regulation were assessed in conditions of limiting glutamine availability. Finally, effects of a combination therapy targeting mTORC1 and glutamine metabolism were studied in WT and KO PDAC cells and preclinical models. Results PI3K-C2γ expression was reduced in about 30% of PDAC cases and was associated with an aggressive phenotype. Similarly, loss of PI3K-C2γ in KPC mice enhanced tumour development and progression. The increased aggressiveness of tumours lacking PI3K-C2γ correlated with hyperactivation of mTORC1 pathway and glutamine metabolism rewiring to support lipid synthesis. PI3K-C2γ-KO tumours failed to adapt to metabolic stress induced by glutamine depletion, resulting in cell death. Conclusion Loss of PI3K-C2γ prevents mTOR inactivation and triggers tumour vulnerability to RAD001 (mTOR inhibitor) and BPTES/CB-839 (glutaminase inhibitors). Therefore, these results might open the way to personalised treatments in PDAC with PI3K-C2γ loss.